American Society of Hematology

Fig. 7.

$Fig. 7. FTI FPT III induces apoptosis in MM cells in the absence and presence of BMSCs. / INA-6 (A), and U266 and Namalwa (B) cells were treated for 3 days with different FPT III concentrations as indicated, and primary MM cells (C) derived from 4 patients (same patients as shown in Figure 1) for 7 days. Primary MM cells were treated with 50 μM FTI FPT III. BMSCs used for coculture assays with INA-6 and primary MM cells were taken from 3 different donors (Figure 1 and see “Materials and methods”). U266 and Namalwa cells were cultured without BMSCs. Apoptosis was analyzed by annexin V-FITC/PI staining. The fraction of viable cells, negative for both annexin and PI, is shown as percentage of untreated control (A + B) or as percentage of total cells (C). Panel A: ♦ indicates +BMSCs; ■, −BMSCs. Panel B: ♦ indicates Namalwa; ■, U266. Panel C: ░ indicates patient 1; ▩, patient 2; ▪, patient 3; and ▧, patient 4. SDs of 3 experiments are shown in panels A and B.$

FTI FPT III induces apoptosis in MM cells in the absence and presence of BMSCs.

INA-6 (A), and U266 and Namalwa (B) cells were treated for 3 days with different FPT III concentrations as indicated, and primary MM cells (C) derived from 4 patients (same patients as shown in Figure 1) for 7 days. Primary MM cells were treated with 50 μM FTI FPT III. BMSCs used for coculture assays with INA-6 and primary MM cells were taken from 3 different donors (Figure 1 and see “Materials and methods”). U266 and Namalwa cells were cultured without BMSCs. Apoptosis was analyzed by annexin V-FITC/PI staining. The fraction of viable cells, negative for both annexin and PI, is shown as percentage of untreated control (A + B) or as percentage of total cells (C). Panel A: ♦ indicates +BMSCs; ■, −BMSCs. Panel B: ♦ indicates Namalwa; ■, U266. Panel C: ░ indicates patient 1; ▩, patient 2; ▪, patient 3; and ▧, patient 4. SDs of 3 experiments are shown in panels A and B.

This Feature Is Available To Subscribers Only